Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Ista Pharmaceuticals Inc.

Pomerantz Haudek Grossman & Gross LLP is investigating claims on behalf of investors of Ista Pharmaceuticals Inc. (“Ista” or the “Company”) (NASDAQ: ISTA) (ISIN: US45031X2045) concerning the proposed acquisition of Ista by Bausch & Lomb Inc. in a cash transaction valued at approximately $500 million.

The investigation concerns whether the Ista directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value. Under the terms of the agreement, Ista shareholders would receive $9.10 in cash per share of Ista common stock. However, at least one analyst has set a target price of $12.00 per share.

Ista shareholders seeking more information about this acquisition are advised to contact Rebecca Jarmon at rjarmon@pomlaw.com or 212-661-1100 or 888-476-6529, ext. 314.

The Pomerantz Firm, with offices in New York, Chicago, and Washington, D.C., is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Copyright Business Wire 2010

If you liked this article you might like

Stocks to Watch: Opnext, Ista (Update 1)

Apollo, Opnext: After-Hours Trading (Update 1)

10 Small-Cap Stocks Poised to Rise, History Shows (Update2)

Valeant Pulls Ista Pharma Takeout Bid

Stocks End Higher on Global Data